TREATMENT OF LATE-LINE HRD+ ADVANCED OVARIAN CANCER AFTER THREE OR MORE CHEMOTHERAPIES WITH ZEJULA

Efficacy Data From the QUADRA Trial


Study Design

QUADRA evaluated ZEJULA as treatment in 4th-line+ patients, including those with BRCA– or platinum-resistant disease1

QUADRA was a single-arm, phase 2 trial of patients (N=463) with advanced ovarian cancer, including HRD+ patients, who had been treated with three or more prior lines of chemotherapy.1,2

Patient characteristics in the QUADRA trial (N=463) were representative of a real-world, late-line population2

  • 27% of patients were 6th line or later
  • 68% of patients were platinum resistant or refractory
QUADRA trial data
QUADRA trial data

The FDA indication is for HRD+ patients (in QUADRA, n=98)* with either1:

  • BRCA+ tumors regardless of platinum status
  • BRCA– tumors with genomic instability (GIS+) and had progressed more than 6 months after the last platinum-based chemotherapy
64 percent

BRCA+

Most BRCA+ patients were platinum resistant or refractory (59%)

36 percent

BRCA-, GIS+ platinum-sensitive

*19% of patients were 6th-line or later.


EFFICACY

Clinically meaningful, durable benefit was observed1,2

Median duration of response in the indicated population

Graph showing the median duration of response in the indicated population.
Graph showing the median duration of response in the indicated population.